Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 16/20 | 0.39 |
| ▸ | HTR1B | P28222 | 11/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | GOT1 | P17174 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14058617 | 0.73 | CYP1A2 (0.40) | KDM4EALDH1A1HPGDHSD17B10NPC1 | |
| SCHEMBL5420045 | 0.70 | ENPP2 (0.43) | MAPK14KDM4EALDH1A1HPGDENPP2 | |
| SCHEMBL19216830 | 0.70 | HTR1D (0.57) | HTR1DHTR1B | |
| SCHEMBL12060780 | 0.66 | AKR1B1 (0.38) | ALDH1A1HPGDNPC1MAPTPKM | |
| SCHEMBL12060765 | 0.66 | NOTUM (0.37) | ALDH1A1HSD17B10NPC1MAPTPKM | |
| SCHEMBL12060933 | 0.66 | MAPT (0.36) | ALDH1A1HSD17B10NPC1MAPTPKM | |
| SCHEMBL7219452 | 0.66 | HTR1D (0.43) | HTR1DHTR1B | |
| SCHEMBL533193 | 0.63 | MAPT (0.44) | HTR1DHTR1BMAPK14KDM4EALDH1A1 | |
| SCHEMBL12060919 | 0.63 | AADAT (0.39) | ALDH1A1HPGDHSD17B10NPC1MAPT | |
| SCHEMBL12061369 | 0.63 | CA1 (0.42) | KDM4EALDH1A1HPGDHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166632-B2 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-20050197380-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2005-09-08 | — | — | US | disclosed |
| US-20050192334-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2005-09-01 | — | — | US | disclosed |
| US-20050187282-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2c, receptor ligands | VERNALIS RESEARCH LIMITED | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197380-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | HTR1D 11/4885HTR1B 8/4885MAPK14 2496/4885 |
| US-20050192334-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | HTR1D 11/4885HTR1B 8/4885MAPK14 2496/4885 |
| US-20050187282-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2c, receptor ligands | HTR2C, HTR2A, HTR1A | HTR1D 11/4885HTR1B 8/4885MAPK14 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.